Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results.

Nat Med · 2022 · PMC9205778 · PMID 35534566

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

CT041 showed a trend of more benefit in patients with higher intratumoral CLDN18.2 expression.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.